Mumbai / New Delhi: Two days after it became public that Ranbaxy Laboratories Ltd is the target of a US litigation that has federal investigators charging that the company did not follow standards in drugs manufacturing and fabricated data in filings with that country's drugs regulator, it has emerged that the company might be at a much bigger risk: expensive class action suits in the world's most litigious nation.